Abstract: The present invention relates to a triphenylene-based compound represented by the following Formula 1 and an organic electroluminescent device including the same, and the compound of the present invention has excellent hole injection and/or transporting ability, electron transporting ability, and/or light emitting ability, and particularly, green and red light emitting ability, and thus in an organic electroluminescent device containing the same as a light emitting host material, characteristics such as luminous efficiency, luminance, thermal stability, driving voltage, service life and the like may be improved. In the formula, each of A, L, X and R1 to R19 is the same as those as defined in Detailed Description.

Abstract: A compound for an organic optoelectronic device, an organic light-emitting device including the same and a display device including the organic light-emitting device are provided, and the compound for an organic optoelectronic device represented by a combination of the following Chemical Formulae 1 and 2 is provided and thus an organic light-emitting device has improved life-span characteristics due to excellent electrochemical and thermal stability, and high luminous efficiency at a low driving voltage.

Abstract: Disclosed are phenyl-oxazolyl derivatives having a general formula (I), a preparation method thereof, and an application of the phenyl-oxazolyl derivatives as an inosine monophosphate dehydrogenase (IMPDH) inhibitor.

Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.

Abstract: Compounds and methods for preventing and treating viral infections are provided. In some embodiments, novel compounds broad-spectrum antiviral activity are provided. In more specific embodiments, the compounds and methods are effective against viruses such as Venezuelan Equine Encephalitis, West Nile Virus, and Hepatitis C.

Abstract: An amine derivative having a phenanthroimidazole group, an organic electroluminescence material, and an electroluminescence device, the amine derivative being represented by Formula 1, below:

Abstract: An arylamine compound is represented by Formula 1. where R, X, Y, and n are further defined.

Abstract: A polymer represented by Formula 1 below: wherein functional groups and n are defined as in the specification.

Abstract: A compound for an organic optoelectronic device is represented by the following Chemical Formula 1:

Abstract: Provided is a method for purifying an organic material having a 10% weight reduction temperature of 250° C. or more as measured by thermogravimetry at a vacuum degree of 1×10?2 Pa or less, which may sublime and purify the organic material having high heat resistance at high sublimation temperature with high purity and high yield in a short period of time, in which the organic material is subjected sublimation purification after a concentration of inorganic impurities in the organic material is adjusted to 5,000 ppm or less.

Abstract: Derivatives of phenothiazine, phenoxazine, and phenazine compounds and their use as ?-synuclein ligands are described. Also described are methods of using these compounds and their radiolabeled analogs for the detection, monitoring, and treatment of synucleinopathies, including Parkinson's disease.

Abstract: A rechargeable metal ion cell comprising: an anode comprising at least one metal; a charge-carrying electrolyte comprising a charge carrying medium and at least one metal salt; and an organic polymer cathode, wherein such cathode comprises at least one N-substituted polyphenothiazine polymer [polymer (P)], such polymer (P) comprising at least one N-substituted phenothiazine recurring unit of formula: wherein R? is an electron-withdrawing group comprising at least one heteroatom selected from the group consisting of O, S, P, and N.

Abstract: The invention provides compositions, medicaments and methods of treating microbial infections, and especially respiratory disorders caused by microbial infections. In particular, the invention relates to the treatment of respiratory diseases caused by pathogenic infections using certain either alkyl substituted or un-substituted 2-aryl acetic acid, or 2-aryl, N-hydroxyacetamide derivatives, or pentoxifylline, and to the use of these compounds in methods of treatment.

Abstract: The invention relates to compounds of general formula IIIa and their use in optoelectronic components.

Abstract: A polymer compound comprising a residue of a compound represented by the following formula (0): wherein Ar0 represents a substituent such as a hydrogen atom, an alkyl group, an alkoxy group, an aryl group and the like, or a group represented by the following formula (A), at least two Ar0s are groups represented by the following formula (A), R0 represents a substituent such as an alkyl group, an alkoxy group, an aryl group and the like, l and m represent an integer of 0 to 3, wherein A0 represents —N? or —C(R2)?. R2 represents a substituent such as a hydrogen atom, an alkyl group, an alkoxy group, an aryl group and the like.

Abstract: The present invention relates to a triphenylene-based compound represented by the following Formula 1 and an organic electroluminescent device including the same, and the compound of the present invention has excellent hole injection and/or transporting ability, electron transporting ability, and/or light emitting ability, and particularly, green and red light emitting ability, and thus in an organic electroluminescent device containing the same as a light emitting host material, characteristics such as luminous efficiency, luminance, thermal stability, driving voltage, service life and the like may be improved. In the formula, each of A, L, X and R1 to R19 is the same as those as defined in Detailed Description.

Abstract: Use of rylene derivatives I with the following definition of the variables: X together both —COOM; Y a radical -L-NR1R2??(y1) -L-Z—R3??(y2) the other radical hydrogen; together both hydrogen; R is optionally substituted (het)aryloxy, (het)arylthio; P is —NR1R2; B is alkylene; optionally substituted phenylene; combinations thereof; A is —COOM; —SO3M; —PO3M2; D is optionally substituted phenylene, naphthylene, pyridylene; M is hydrogen; alkali metal cation; [NR5]4+; L is a chemical bond; optionally indirectly bonded, optionally substituted (het)arylene radical; R1, R2 are optionally substituted (cyclo)alkyl, (het)aryl; together optionally substituted ring comprising the nitrogen atom; Z is —O—; —S—; R3 is optionally substituted alkyl, (het)aryl; R? is hydrogen; optionally substituted (cyclo)alkyl, (het)aryl; R5 is hydrogen; optionally substituted alkyl (het)aryl; m is 0, 1, 2; n, p m=0: 0, 2, 4 where: n+p=2, 4, if appropriate 0; m=1: 0, 2, 4 where: n+p=0, 2, 4; m=2: 0, 4, 6

Abstract: Novel compounds, methods, and compositions for treating various viral infections are described. In some embodiments the novel compounds of the invention are 3-oxo-phenothiazine derivatives; more specific embodiments include 3-oxo-phenothiazine derivatives having substituents at the 1-, 7-, and 9-positions of the phenothiazine parent ring. In other embodiments, the invention provides compositions and methods for treating viral infections, especially HIV.

Abstract: [Problem] An organic compound of excellent characteristics is provided that exhibits excellent hole-injecting/transporting performance with electron blocking ability, and that has high stability in the thin-film state and high luminous efficiency, the organic compound being provided as material for an organic electroluminescent device having high efficiency and high durability. The invention also provides a high-efficient, high-durable organic electroluminescent device using the compound. [Means for Resolution] The compound is of the following general formula having a carbazole ring structure. The organic electroluminescent device includes a pair of electrodes, and one or more organic layers sandwiched between the pair of electrodes, and the compound is used as a constituent material of at least one organic layer.

Abstract: This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

Abstract: Silanes comprising phenothiazine S-oxide or phenothiazine S,S-dioxide groups, organic light-emitting diodes comprising the inventive silanes, a light-emitting layer comprising at least one inventive silane and at least one triplet emitter, a process for preparing the inventive silanes and the use of the inventive silanes in organic light-emitting diodes, preferably as matrix materials and/or blocker materials for triplet emitters.

Abstract: The present invention relates to novel Tricyclic Heterocycle Derivatives, pharmaceutical compositions comprising the Tricyclic Heterocycle Derivatives and the use of these compounds for treating or preventing allergy, an allergy-induced airway response, congestion, a cardiovascular disease, an inflammatory disease, a gastrointestinal disorder, a neurological disorder, a metabolic disorder, obesity or an obesity-related disorder, diabetes, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. R1 is formula (Ia), (Ib) or (Ic); R2 is alkvl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl. any of which can be optionally substituted with R11; M1 is —CH—. —C(halo)- or —N—; Y is —C(O)—, —S—. —S(O)—, —S(O)2—, —CH2— or —O—, such that Y is not —O— when an adjacent atom is N.

Abstract: The present invention pertains to an electrode layer comprising a porous film made of oxide semiconductor fine particles sensitized with certain methin dyes. Moreover the present invention pertains to a photoelectric conversion device comprising said electrode layer, a dye sensitized solar cell comprising said photoelectric conversion device and to novel methin dyes.

Abstract: An organic light-emitting device including a first electrode, a second electrode, and an organic layer interposed between the first electrode and the second electrode. The organic layer includes at least one organosiloxane compound selected from organosiloxane compounds represented by An organic light-emitting device using the organosiloxane compound has a low operating voltage, high color purity, and high efficiency.

Abstract: A process is described for preparing, efficiently and with a high degree of purity N-alkylsulfonates of phenothiazine. The process consists in (a) the preparation of the phenothiazine anion, and (b) the reaction of said anion with cyclic alkyl sulfonates, such as 1,3-propane sultone and 1,4-butane sultone. This process is simpler, more direct, and more efficient than the procedures currently used for the synthesis of N-alkylsulfonates derivatives of phenothiazine. In addition, the products obtained with this process are far more pure than those obtained through current procedures and therefore ideal for bioanalytical applications that require high sensitivity, such as assays based on the measurement of peroxidase activity using chemiluminescence.

Abstract: Enantomerically purified phenothiazines are provided as active ingredients of medicaments to limit activity of bone resorbing cells so as to reduce bone loss. Novel phenothiazine derivatives are provided. A method of synthesizing enantiomerically pure phenothiazine derivatives is provided that avoids post-synthetic enantiomeric resolution.

Abstract: A polymer compound comprising a residue of a compound of the following formula (1): (wherein, a ring C1, ring C2 and ring C3 represent each independently an aromatic hydrocarbon ring or hetero ring. A1 represents a di-valent group containing one or more atoms selected from a boron atom, carbon atom, nitrogen atom, oxygen atom, phosphorus atom, sulfur atom and selenium atom. R1 represents an alkyl group, alkoxy group, alkylthio group, aryl group, aryloxy group, arylthio group, arylalkyl group, arylalkyloxy group, arylalkylthio group, alkenyl group, alkynyl group, di-substituted amino group, tri-substituted silyl group, acyl group, acyloxy group, imine residue, amide group, acid imide group, mono-valent heterocyclic group, substituted carboxyl group, heteroaryloxy group or heteroarylthio group, or is connected to an atom adjacent to an atom on the ring C3 to which R1 is connected, to form a ring.).

Abstract: The present invention relates to substituted phenothiazines with a double bond and physiologically acceptable salts thereof, and their use as a medicament.

Abstract: Silanes comprising phenothiazine S-oxide or phenothiazine S,S-dioxide groups, organic light-emitting diodes comprising the inventive silanes, a light-emitting layer comprising at least one inventive silane and at least one triplet emitter, a process for preparing the inventive silanes and the use of the inventive silanes in organic light-emitting diodes, preferably as matrix materials and/or blocker materials for triplet emitters.

Abstract: The present invention discloses dye-sulfenate derivatives and their bioconjugates for dual phototherapy of tumors and other lesions. The compounds of the present invention may contain either a mixture of Type 1 and Type 2 agents or a single entity that integrates both units in the same molecules. The compounds are designed to produce both Type 1 and Type 2 phototherapeutic effect at once using dual wavelength light source that will produce singlet oxygen and free radicals at the lesion of interest.

Abstract: The compounds of the present invention are of formula I: wherein A, R3, R4 is as defined herein, are useful as ligands for nicotinic receptors.

Abstract: It relates to a dye compound for solar cells, a dye-sensitized photoelectric converter and dye-sensitized solar cells. The photoelectric conversion efficiency of solar cells is improved by using the dye compound for solar cells, expressed by formula 1: in which X is at least one aromatic group and symmetric about the X—R1 bond axis or at least hetero aromatic group having at least one hetero atom chosen from N and S and symmetric about the X—R1 bond axis; R1 is C1 to C20 cyclic substituted or unsubstituted alkyl or C1 to C20 linear substituted or unsubstituted alkyl; L1 and L2 are substituted or unsubstituted hydrocarbons having 2 to 8 conjugated p-orbitals; Y1 and Y2 are better electro-withdrawing group than X and may contain at least one acidic hydrogen which is able to have hydrogen bond.

Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.

Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.

Abstract: The present invention relates to novel organic electroluminescent compounds, and organic electroluminescent devices comprising the same as electroluminescent material. Specifically, the organic electroluminescent compounds according to the invention are characterized in that they are represented by Chemical Formula (1): wherein, L1 is a substituent selected from the following structures; A and B independently represent a chemical bond, or a substituent selected from the following structures; m and n independently represent an integer from 0 to 4; provided that, if represents both X1 and X2 represent NR33, and both Y1 and Y2 represent a chemical bond, then R33 does not represent hydrogen or (C1-C5)alkyl. The organic electroluminescent compounds according to the invention exhibit high luminous efficiency in blue color and excellent life property of material, so that an OLED having very good operation life can be prepared therefrom.

Abstract: The invention concerns amidine derivatives of general formula (I) exhibiting an inhibitory activity of calpains and/or a trapping activity of reactive forms of oxygen.

Abstract: The present invention relates to compounds according to formula (1) and/or according to formulae (4) to (10) and their use in organic electroluminescent devices, in particular as a matrix material in phosphorescent devices.

Abstract: The invention describes novel organic nitric oxide enhancing salts of nonsteroidal antiinflammatory drugs (NSAIDs) and novel compositions comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides novel compositions and kits comprising at least one organic nitric oxide enhancing salt of an NSAID, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent.

Abstract: A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.

Abstract: The present invention relates to a benzamide derivative comprising a head, spacer and cap group wherein the spacer includes a benzene ring substituted with an additional spacer and wherein the additional spacer is an unsaturated group.

Abstract: The present invention relates to crystalline R-guanidines of (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparations and its use as therapeutic agents. More specifically the present invention relates to crystalline Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, preferably (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H-phenoxazin-10-yl)ethoxy]phenyl}propanoate, its preparation and its use as therapeutic agent.

Abstract: This disclosure provides a new class of compounds referred to as “reversed chloroquines” (RCQs), which are highly effective against CQR and CQS malaria parasites. RCQs are hybrid molecules, which include an antimalarial quinoline analog (such as chloroquine) moiety and a CQR reversal moiety. Exemplary RCQ chemical structures are provided. Also provided are pharmaceutical compositions including the disclosed RCQ compounds, and methods of using such compounds and compositions for the treatment of malaria and inhibition of CQR or CQS Plasmodium sp. (such as P. falciparum).

Abstract: A process is described for preparing, efficiently and with a high degree of purity N-alkylsulfonates of phenothiazine. The process consists in (a) the preparation of the phenothiazine anion, and (b) the reaction of said anion with cyclic alkyl sulfonates, such as 1,3-propane sultone and 1,4-butane sultone. This process is simpler, more direct, and more efficient than the procedures currently used for the synthesis of N-alkylsulfonates derivatives of phenothiazine. In addition, the products obtained with this process are far more pure than those obtained through current procedures and therefore ideal for bioanalytical applications that require high sensitivity, such as assays based on the measurement of peroxidase activity using chemiluminescence.

Abstract: A method of treating or preventing of a disease or condition associated with an increased level of isoforms of amyloid ? peptides (A?) and/or with a changed ratio of levels of A? isoforms and/or with the formation of plaques containing amyloid ? peptide (A?) isoforms in a mammal comprising administering to said mammal an therapeutically effective amount of a compound selected from the formulas Ia, Ib wherein V, W, Y, R2, R3, R5, R6, L1 and i are defined as in claim 1.

Abstract: A hydroxytetrahydrofuran of formula wherein A is with the substituents as defined in the specification, having a calpain inhibiting activity and/or an activity which traps the reactive oxygen species useful for treating inflammatory and immunological diseases, cardio-vascular and cerebro-vascular diseases, disorders of the central or peripheral nervous system, osteoporosis, muscular dystrophy, proliferative diseases, cataract, rejection reactions following organ transplants and autoimmune and viral diseases.

Abstract: A light-emitting compound that has excellent carrier transportation properties and that can exhibit long wavelength light is disclosed. Further, a method for manufacturing the light-emitting compound in a high yield is disclosed. The disclosed light-emitting compound is a pyran derivative as represented by general formula 1: wherein A1 and A2 are individually a ?-conjugated system group having 6 to 16 conjugating carbon atoms; X1 is a dialkylamino group; and Y1 is a diarylamino group or an alkylarylamino group.

Abstract: A cyclopentaphenanthrene-based compound is easy to prepare and excellent in solubility, color purity, color stability, and thermal stability. The cyclopentaphenanthrene-based compound is useful as a material for forming an organic layer, in particular, an emitting layer, in an organoelectroluminescent device, and as an organic dye or an electronic material such as a nonlinear optical material.

Abstract: A compound for use in electrochromic devices. The compound includes (1) ?-(10-phenothiazyl)propoxy phosphonic acid; (2) ?-(10-phenothiazyl)propyl-phosphonic acid; and (3) ?-(10-phenothiazyl)propionate phosphonic acid.

Abstract: A method for stabilizing an arylcarboxylic acid, which comprises adding a heterocyclic base to the arylcarboxylic acid or a pharmacologically acceptable salt thereof, a stabilizer thereof and an aqueous solution containing a stabilized arylcarboxylic acid. According to the stabilization method of the present invention, arylcarboxylic acid and pharmacologically acceptable salts thereof, particularly pranoprofen, can be stabilized at every temperature range, particularly at lower temperatures, thereby making the production of an aqueous solution to be used as an eye drop, nasal drop, ear drop and the like possible.

Abstract: Compounds of formula (I): [in which: R1 represents a direct bond, an oxygen atom, a group >CH2, a sulphur atom, a group >C?O, a group —(CH2)2— or a group of formula —N—Ra, where Ra is hydrogen or an alkyl; R4, R5, R6 and R7 are each hydrogen or various groups or atoms; R8, R9, R10 and R11 are each hydrogen, hydroxy, or alkyl; or R9 and R11 form a fused ring system with the benzene rings to which they are attached; R12 is a direct bond, oxygen atom or methylene; and X? is an anion; and esters thereof] are useful as cationic photoinitiators, especially for use in surface coating applications, such as printing inks and varnishes, and which are intended to be cured by polymerisation initiated by radiation.